Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct 12;366(1579):2782-9.
doi: 10.1098/rstb.2011.0097.

Tuberculosis vaccines: beyond bacille Calmette-Guerin

Helen McShane  1
Affiliations
Review

Tuberculosis vaccines: beyond bacille Calmette-Guerin

Helen McShane. Philos Trans R Soc Lond B Biol Sci. .

Abstract

Tuberculosis (TB) disease caused by Mycobacterium tuberculosis (M. tb) remains one of the leading infectious causes of death and disease throughout the world. The only licensed vaccine, Mycobacterium bovis bacille Calmette-Guérin (BCG) confers highly variable protection against pulmonary disease. An effective vaccination regimen would be the most efficient way to control the epidemic. However, BCG does confer consistent and reliable protection against disseminated disease in childhood, and most TB vaccine strategies being developed incorporate BCG to retain this protection. Cellular immunity is necessary for protection against TB and all the new vaccines in development are focused on inducing a strong and durable cellular immune response. There are two main strategies being pursued in TB vaccine development. The first is to replace BCG with an improved whole organism mycobacterial priming vaccine, which is either a recombinant BCG or an attenuated strain of M. tb. The second is to develop a subunit boosting vaccine, which is designed to be administered after BCG vaccination, and to enhance the protective efficacy of BCG. This article reviews the leading candidate vaccines in development and considers the current challenges in the field with regard to efficacy testing.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Gantt chart summarizing clinical trials with MVA85A since 2002.
See this image and copyright information in PMC

References

    1. World Health Organization 2010. Global tuberculosis control. Geneva, Switzerland: WHO Press
    1. World Health Organization 2011. The global plan to stop TB 2011–2015. See http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB....
    1. Rodrigues L. C., Diwan V. K., Wheeler J. G. 1993. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 22, 1154–115810.1093/ije/22.6.1154 (doi:10.1093/ije/22.6.1154) - DOI - DOI - PubMed
    1. Sterne J. A., Rodrigues L. C., Guedes I. N. 1998. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. 2, 200–207 - PubMed
    1. Trunz B. B., Fine P., Dye C. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367, 1173–118010.1016/S0140-6736(06)68507-3 (doi:10.1016/S0140-6736(06)68507-3) - DOI - DOI - PubMed

Publication types

MeSH terms